PVI
BVS icon

Pura Vida Investments’s Bioventus BVS Stock Holding History

Pura Vida Investments’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150,000
Closed -$1.57M – 9
2024
Q4 		$1.57M Buy
+150,000
New +$1.77M 4.98% 9

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pura Vida Investments's BVS Position: Q4 2024 in Review

Pura Vida Investments sold out of Bioventus (BVS) in Q4 2024, closing a stake of 352,569 shares — an estimated $4.17M sold.

Pura Vida Investments first reported a position in BVS in Q1 2021 and held it in 10 quarters. The position peaked at $13.4M in Q1 2021. 151 funds tracked by Wall St. Rank hold BVS as of Q4 2024.

  • Pura Vida Investments reported no remaining Bioventus position as of Q4 2024 after selling out during the quarter.
  • Pura Vida Investments sold 352,569 Bioventus shares in Q4 2024, an estimated $4.17M.
  • Pura Vida Investments first reported a position in Bioventus in Q1 2021 and held it in 10 quarters.
  • Pura Vida Investments's Bioventus position peaked at $13.4M in Q1 2021.
  • 151 funds tracked by Wall St. Rank held Bioventus as of Q4 2024.

Based on Pura Vida Investments's 13F filing for Q4 2024, filed 12 Feb 2025.